Preparation method and application of arsenic compound

By preparing the new arsenic compound Lig-o-As, it is used to inhibit the activity of thioredoxin reductase, the shortcomings of arsenic compounds in the prior art in inhibiting tumor cells and effectively killing tumor cells is achieved and oxidative stress effects.

CN119080840APending Publication Date: 2024-12-06LANZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411172008.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing arsenic compounds have limited effects in inhibiting the activity of thioredoxin reductase and are difficult to effectively kill tumor cells.

Method used

By preparing a new arsenic compound, its structure is (E)-N-(2-(1,3,2-dithiasinan-2-yl)phenyl)-3-(3,5,6-trimethylpyrazin-2 -yl)acrylamide (Lig-o-As), a compound inhibits the activity of the enzyme and kills tumor cells by inhibiting the selenocysteine ​​site at the carbon end of the thioredoxin reductase. The preparation method of the compound includes dissolving the ligustrazine derivative in an ice bath, adding triethylamine and valeryl chloride, rotary evaporation, adding DMAP and triethylamine, subsequent reaction with the intermediate, and separation of the final product using thin layer chromatography.

Benefits of technology

This compound significantly inhibits the activity of thioredoxin reductase, leads to apoptosis of tumor cells, and shows strong cytotoxicity and oxidative stress effects in vitro and in vivo, which can effectively kill HL-60 cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080840A_ABST
    Figure CN119080840A_ABST
Patent Text Reader

Abstract

The invention aims to disclose a preparation method and application of an arsenic compound. At present, arsenic trioxide (ATO) is used as a clinical treatment medicine and is used for treating various malignant diseases, particularly acute promyelocytic leukemia (APL). In recent years, a plurality of novel organic arsenic drugs for targeted delivery of tumors are also successively clinically, and Darinaparsin has been approved in Japan for treatment of peripheral T-cell lymphoma. Compared with inorganic arsenic, organic arsenic is generally more stable, the structure is easier to modify, and better biocompatibility is achieved. According to the invention, arsenic benzene oxide (PAO) is used as a parent molecule for structural modification to obtain two novel organic arsenic compounds, and a biological activity test shows that the compounds can kill tumor cells by inhibiting the activity of TrxR.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of chemical medicine, and in particular to a method for preparing an arsenic compound and its use Background Art

[0002] At present, the main treatments for cancer include traditional methods (such as surgery, chemotherapy, and radiotherapy) and new methods (such as immunotherapy). Chemotherapy, as a systemic treatment method, still plays a very important role in current cancer treatment. Arsenic compounds have a long history of use as traditional prescription ingredients in ancient civilizations of the East and the West. Among them, arsenic (As2O3), realgar (As4S4), and orpiment (As2S3) are often used as antibiotics in a variety of infectious diseases. In particular, arsenic trioxide (ATO) has been used as a clinical treatment drug for acute promyelocytic leukemia (APL). In recent years, a variety of organoarsenic drugs for tumor-targeted delivery have also entered the clinic, among which Darinaparsin has been approved in Japan for the treatment of peripheral T-cell lymphoma. Compared with inorganic arsenic, organic arsenic is generally more stable, easier to modify in structure, and has better biocompatibility. Studies have shown that trivalent organic arsenic can covalently react with the sulfhydryl side chains of cysteine ​​residues of various proteins in the body, thereby affecting protein activity to exert drug efficacy. Therefore, the use of trivalent arsenic functional groups as covalent warheads to prepare targeted covalent inhibitors has a good application prospect. Thioredoxin reductase (TrxR) is a selenium-containing homodimeric flavin enzyme present in cells. It is overexpressed in a variety of tumor tissues and affects the survival, proliferation and apoptosis of tumor cells. Killing tumor cells by inhibiting the activity of TrxR with chemical drugs has become an effective cancer targeted treatment strategy. Summary of the invention

[0003] Based on the current status of the above-mentioned prior art research, the present invention provides a preparation method and use of arsenic compounds. The arsenic compounds of the present invention have a good inhibitory effect on the activity of thioredoxin reductase, and it is found that such molecules inhibit the activity of thioredoxin reductase by inhibiting the selenocysteine ​​at the carbon terminal of thioredoxin reductase, thereby killing tumor cells.

[0004] Specifically, the present invention provides an arsenic compound, the structure of which is shown in the following formula (I):

[0005]

[0006] The present invention also provides a use of arsenic compounds, specifically, inhibiting the activity of thioredoxin reductase by inhibiting selenocysteine ​​at the carbon terminal of thioredoxin reductase, thereby killing tumor cells.

[0007] The specific preparation method of the arsenic compound of the present invention is as follows: Under an ice bath, 1 equivalent of ligustrazine derivative is dissolved in an anhydrous dichloromethane solution, then 1.5 mL of triethylamine is added and stirred for ten minutes, and then 2 equivalents of pivaloyl chloride are added. After two hours, dichloromethane is removed by a rotary evaporator to obtain an intermediate. Then, the arsenic compound is dissolved in anhydrous dichloromethane, 6 mg of DMAP and 1.5 mL of triethylamine are added, stirred for half an hour, and then the prepared anhydrous dichloromethane solution of the intermediate is added. After stirring for half an hour, the room temperature is gradually restored and stirred until the raw materials are completely reacted. The reaction progress is detected by thin layer chromatography. After the reaction is completed, a saturated ammonium chloride solution is added to quench the reaction, and the dichloromethane is extracted, dried over anhydrous sodium sulfate, and the organic phases are combined. Thin layer chromatography is used to separate the final target compound. BRIEF DESCRIPTION OF THE DRAWINGS

[0008] Figure 1 This is a schematic diagram of the cytotoxic activity results of the two arsenic compounds synthesized in Experimental Example 1 on HL-60 cells.

[0009] Figure 2 This is a schematic diagram of the inhibition results of the compound Lig-o-As on the activity of thioredoxin reductase and related enzymes in vitro.

[0010] Figure 3 This is a schematic diagram of the increase in reactive oxygen species after the compound Lig-o-As inhibits the activity of thioredoxin reductase in HL-60 cells. Figure 4 The present invention provides an arsenic compound, the structure of which is shown in the following formula (I):

[0011] Embodiment 1:

[0012] (E)-N-(4-(1,3,2-dithiarsinan-2-yl)phenyl)-3-(3,5,6-trimethylpyrazin-2-yl)acrylamide(Lig-p-As) 1 H NMR (400MHz, CDCl3) δ7.95(d,J=14.7Hz,1H),7.86(d,J=8.2Hz,2H),7.74(d,J=8.1Hz,2H),7.57(s,1H),7.21(d,J=14.7Hz,1H),2.83(ddd ,J=13.6,11.1,2.2Hz,2H),2.67(ddd,J=14.1,6.5,2.4Hz,2H),2.62(s,3H),2.51(d,J=4.6Hz,6H),2.23–2.07(m,1H),2.01–1.87(m,1H).

[0013] Embodiment 2:

[0014] (E)-N-(2-(1,3,2-dithiarsinan-2-yl)phenyl)-3-(3,5,6-trimethylpyrazin-2-yl)acrylamide(Lig-o-As) 1 H NMR (400MHz, CDCl3) δ9.51(s,1H),8.22(d,J=8.1Hz,1H),7.99–7.92(m,2H),7.50(t,J=7.8Hz,1H),7.29(d,J=7.4Hz,1H),7.22(s,1H ),2.98–2.94(m,2H),2.89(q,J=2.7Hz,2H),2.64(s,3H),2.54(d,J=2.5Hz,6H),2.24(q,J=11.9Hz,1H),2.05(dd,J=14.6,7.0Hz,1H).

[0015] Test Example 1: Cytotoxicity test of Example 1 and Example 2 (two arsenic compounds) on HL-60 cells

[0016] Experimental method: 5000 HL-60 cells were added to each well of a 96-well plate, and the compounds in Example 1 and Example 2 were respectively treated for 48 hours. Finally, the cytotoxic activity of the compounds was determined by the MTT method.

[0017] Experimental results: The results are as follows Figure 1 As shown, the results show that Example 2 has strong cytotoxicity to HL-60 cells.

[0018] Experimental Example 2: In vitro inhibition data of thioredoxin reductase-related enzyme activities by the compound of Example 2 (Lig-o-As) Experimental method: The inhibition of various enzyme activities in vitro by Example 2 was determined according to the method of the literature “Duan, D.; Zhang, B.; Yao, J.; Liu, Y.; Sun, J.; Ge, C.; Peng, S.; Fang, J.; Free Radical Biol. Med. 2014, 69, 15-25” (U498C TrxR: the enzyme is Sec at position 498 of TrxR mutated to Cys.).

[0019] Experimental results: The results are as follows Figure 2 As shown, the compound of Example 2 inhibits the activity of thioredoxin reductase by selectively acting on the selenocysteine ​​active site at the C-terminus of TrxR.

[0020] Experimental Example 3: Changes in active oxygen in Example 2 after acting on HL-60 cells Experimental method: The changes in active oxygen in Example 2 after acting on HL-60 cells were determined according to the method of the literature “Duan, D.; Zhang, B.; Yao, J.; Liu, Y.; Sun, J.; Ge, C.; Peng, S.; Fang, J.; Free Radical Biol. Med. 2014, 69, 15-25”.

[0021] Experimental results: The results are as follows Figure 3 As shown, after Example 2 acted on HL-60 cells, the intracellular redox balance was broken and the level of reactive oxygen species increased, further indicating that Example 2 caused intracellular redox imbalance after acting on HL-60 cells, thereby causing oxidative stress and leading to HL-60 death.

[0022] Experimental Example 4: Cell apoptosis after Example 2 acted on HL-60 cells Experimental method: The cell apoptosis after Example 2 acted on HL-60 cells was determined according to the method of the literature “Duan, D.; Zhang, B.; Yao, J.; Liu, Y.; Sun, J.; Ge, C.; Peng, S.; Fang, J.; Free Radical Biol. Med. 2014, 69, 15-25”.

[0023] Experimental results: The results are as follows Figure 4 As shown, Example 2 kills HL-60 cells mainly by inducing apoptosis. Figure 4 Four different cell populations are shown, marked as follows: double negative (unstained) cells showing live cell populations (lower left, Q3), Annexin V positive and PI negative stained cells showing early apoptosis (lower right, Q4), Annexin V / PI double stained cells showing late apoptosis (upper right, Q2), and finally PI positive and Annexin V negative stained cells showing dead cells (upper left, Q1). As the concentration of Example 2 gradually increases and the time is prolonged, the number of apoptotic cells also gradually increases, and the number of cells entering late apoptosis is also increasing, while the number of necrotic cells is not significantly different from the control group, indicating that Example 2 kills HL-60 cells mainly by inducing apoptosis.

Claims

1. The present invention discloses a preparation method and use of an arsenic compound. The two arsenic compounds of the present invention have structures shown in the following formula (I). The arsenic compounds of the present invention have an inhibitory effect on the activity of thioredoxin reductase, thereby killing tumor cells; 2. Two arsenic compounds, characterized in that: Its structure is shown in the following formula (I):

3. A new use of arsenic compounds as claimed in claim 1, characterized in that: Its structure is shown in the above formula (I), and it is used to prepare active drug molecules that kill tumor cells by inhibiting thioredoxin reductase.